Previous 10 | Next 10 |
home / stock / bovnf / bovnf news
LUND,Sweden, July 22, 2020 /PRNewswire/ -- . Alexander Eggermont , MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad potential of BI-1206 in enhancing checkpoint inhibitors in solid cancers in a KOL event h...
LUND, Sweden , July 1, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer Inc. ("Pfi...
BioInvent International ( OTC:BOVNF ) submits a clinical trial application to commence Phase 1/2a study of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2), as a single agent, as well as in combination with Merck's Keytruda, for solid tumors an...
LUND, Sweden , June 30, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a clini...
BioInvent International AB ( OTC:BOVNF ) enrolls first patient in a Phase I/IIa clinical trial of BI-1206 in combination with collaborator Merck's (NYSE: MRK ) anti-PD-1 therapy KEYTRUDA (pembrolizumab) for patients with solid tumors. More news on: BioInvent International AB (publ), Merc...
- AACR abstract outlines two monoclonal antibodies selected for further development, BI-1808 and BI-1910 - Both generated using our proprietary n-CoDeR ® library and F.I.R.S.T TM technology - First in human trial with the lead candidate BI-1808 - a ligand-blocking FcgR-...
BioInvent International ( OTC:BOVNF ): Q1 GAAP EPS of -SEK0.07. More news on: BioInvent International AB (publ), Earnings news and commentary, Healthcare stocks news, , Read more ...
LUND, Sweden , April 28, 2020 /PRNewswire/ -- Promising progress reported for BI-1206 in combination with rituximab "We have made a strong start to 2020 and remain on track to deliver on our goals. Our lead candidate, BI-1206, continues to make good progress, while we are developi...
- Complete response in one follicular lymphoma (FL) patient - Complete depletion of circulating tumoral cells in a mantle cell lymphoma (MCL) patient LUND, Sweden , April 14, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today provides...
LUND, Sweden , Feb. 24, 2020 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) will issue its interim report for the fourth quarter 2019 on Thursday February 27 at 7.30 a.m. CET , followed by an audiocast with teleconference at 8.30 a.m. CET , hosted by Martin Welschof, CEO and ...
News, Short Squeeze, Breakout and More Instantly...
LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors Initial...
LUND, SE / ACCESSWIRE / July 17, 2024 / BioInvent International (STO:BINV) Agreement to support expansion of BI-1607 program with new Phase 2 triplet combination study in metastatic melanoma The study will evaluate anti-FcγRIIB antibody BI-1607 with low-dose anti-CTLA-4, ipilimu...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...